+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bladder Cancer Therapeutics Market by Therapeutic Approach (Chemotherapy, Combination Therapy, Immunotherapy), Treatment Stage (Metastatic, Muscle-Invasive, Non-Muscle-Invasive), Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Bladder Cancer Therapeutics Market by Therapeutic Approach (Chemotherapy, Combination Therapy, Immunotherapy), Treatment Stage (Metastatic, Muscle-Invasive, Non-Muscle-Invasive), Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

Bladder Cancer Therapeutics Market by Therapeutic Approach (Chemotherapy, Combination Therapy, Immunotherapy), Treatment Stage (Metastatic, Muscle-Invasive, Non-Muscle-Invasive), Treatment Line, Administration Route, Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010937
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The bladder cancer therapeutics market is advancing, characterized by rapid innovation, evolving regulatory landscapes, and new treatment modalities. Senior leaders evaluating this sector require actionable insights into current developments, market structure, and the factors impacting global access to advanced bladder cancer treatments.

Market Snapshot: Bladder Cancer Therapeutics Market Overview

The bladder cancer therapeutics market grew from USD 5.56 billion in 2024 to USD 5.97 billion in 2025. It is expected to continue growing at a CAGR of 7.33%, reaching USD 8.50 billion by 2030. This growth reflects an industry responding to scientific breakthroughs, patient-centered innovations, and increased investment in novel agents. Market activity is shaped by both traditional chemotherapy and an expanding ecosystem of biologics, targeted therapies, and immunomodulators. As regulatory frameworks adapt to accommodate emerging modalities, senior leaders must assess opportunities and risks in a market trending toward multi-modal solutions and precision oncology.

Scope & Segmentation of the Bladder Cancer Therapeutics Market

This report provides a comprehensive segmentation of the bladder cancer therapeutics market, analyzing each key facet influencing industry direction and patient outcomes:

  • Therapeutic Approaches: Chemotherapy (non-platinum and platinum-based), combination therapies integrating immuno-oncology and targeted agents, immunotherapies (cell therapy, checkpoint inhibitors, cytokines, vaccines), novel therapies (gene therapy, nanomedicine, oncolytic viruses), photodynamic therapy, and targeted therapy (EGFR, FGFR, HER2 inhibitors).
  • Treatment Stages: Non-muscle-invasive, muscle-invasive, and metastatic stages, guiding clinical intervention strategies.
  • Treatment Lines: First, second, and third lines of treatment, illustrating shifts in response and resistance management.
  • Administration Routes: Intravenous, intravesical, and oral routes selected to optimize efficacy and patient convenience.
  • Distribution Channels: Hospital pharmacy, retail pharmacy, and online pharmacy, reflecting evolving procurement and access pathways.
  • End Users: Hospitals, specialty clinics, and home healthcare, each impacting adoption and patient care models.
  • Regional Coverage: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (featuring the UK, Germany, France, and others), and Asia-Pacific (China, India, Japan, Australia, and more).
  • Corporate Landscape: Analysis includes companies such as Merck & Co., Inc., F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Pfizer Inc., and others at the forefront of innovation.

Key Takeaways for Decision-Makers

  • Immune-based and molecularly targeted therapies are rapidly changing standard treatment paradigms by driving improved outcomes in specialized patient cohorts.
  • Combination regimens are emerging as a new standard, challenging monotherapy and increasing demand for individualized approaches based on precise biomarker profiles.
  • Technological advances in manufacturing, delivery systems, and real-world data collection are streamlining the progression from bench to bedside and accelerating regulatory review.
  • Supply chain strategies are evolving to prioritize risk mitigation and cost containment, as global events and economic measures continue to introduce potential instability.
  • Regional markets display significant variation in adoption rates, access to advanced treatments, and infrastructure readiness, requiring tailored go-to-market strategies.
  • Collaboration between established pharmaceutical leaders and biotechs is accelerating the development of next-generation compounds and companion diagnostics, strengthening pipelines and differentiation.

Impact of 2025 U.S. Tariff Measures

Recent tariff policies introduced in the United States have added operational challenges for manufacturers and their partners. Companies have adjusted sourcing and production approaches, often reviewing contract terms and seeking alternative manufacturing sites to maintain continuity and control costs. Inventory and launch strategies have become more conservative, prompting broader collaboration across industry stakeholders to strengthen supply resilience while maintaining patient access to therapies.

Methodology & Data Sources

This report utilizes both primary and secondary research, including in-depth interviews with healthcare experts and exhaustive reviews of clinical and industry literature. Multiple data points were validated through cross-referencing, enhancing confidence in the findings. Scenario analysis was used to assess the implications of changing policy and reimbursement environments.

Why This Report Matters

  • Informs investment and R&D decisions with a detailed view of emerging technologies and therapeutic innovations, supporting long-term growth planning.
  • Equips executive teams with actionable intelligence to address evolving regulatory hurdles and cost pressures in diverse regional markets.
  • Enables optimization of supply chain and market access strategies by revealing the interplay of economic, clinical, and operational factors shaping patient outcomes.

Conclusion

The bladder cancer therapeutics market is defined by dynamic shifts in technology use, regulatory adaptation, and supply chain strategy. Organizations equipped with data-driven insight can more effectively position themselves to lead in this evolving therapeutic area.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of antibody-drug conjugates targeting novel bladder cancer antigens as frontline therapy
5.2. Integration of predictive biomarkers to personalize immunotherapy regimens for muscle-invasive bladder cancer
5.3. Development of targeted FGFR inhibitors and their impact on progression in bladder carcinoma
5.4. Exploration of neoadjuvant immunotherapy combinations to enhance pathologic complete response rates
5.5. Implementation of liquid biopsy approaches for real-time monitoring of tumor mutational burden in bladder cancer
5.6. Trials investigating intravesical delivery of gene therapy vectors to reduce tumor recurrence post TURBT
5.7. Emergence of bispecific T-cell engager therapies boosting immune activation in refractory bladder cancer
5.8. Evaluating cost-effectiveness of emerging therapies in non-muscle-invasive bladder cancer management pathways
5.9. Advances in patient stratification using ctDNA profiling to guide maintenance therapy decisions
5.10. Regulatory approvals influencing the market uptake of novel checkpoint inhibitors in bladder cancer
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Bladder Cancer Therapeutics Market, by Therapeutic Approach
8.1. Introduction
8.2. Chemotherapy
8.2.1. Non-Platinum
8.2.1.1. Gemcitabine
8.2.1.2. Taxanes
8.2.2. Platinum-Based
8.2.2.1. Carboplatin
8.2.2.2. Cisplatin
8.3. Combination Therapy
8.3.1. Chemo Plus Immuno
8.3.2. Chemo Plus Targeted
8.3.3. Immuno Plus Targeted
8.4. Immunotherapy
8.4.1. Cell Therapy
8.4.1.1. Car-T
8.4.1.2. Til Therapy
8.4.2. Checkpoint Inhibitors
8.4.2.1. Ctla-4 Inhibitors
8.4.2.2. Pd-1 Inhibitors
8.4.2.3. Pd-L1 Inhibitors
8.4.3. Cytokines
8.4.3.1. Ifn-Alpha
8.4.3.2. Il-2
8.4.4. Vaccines
8.4.4.1. Bacillus Calmette-Guérin
8.4.4.2. Dendritic Cell
8.4.4.3. Peptide-Based
8.5. Novel Therapy
8.5.1. Gene Therapy
8.5.2. Nanomedicine
8.5.3. Oncolytic Virus
8.6. Photodynamic Therapy
8.7. Targeted Therapy
8.7.1. Egfr Inhibitors
8.7.2. Fgfr Inhibitors
8.7.3. Her2 Inhibitors
9. Bladder Cancer Therapeutics Market, by Treatment Stage
9.1. Introduction
9.2. Metastatic
9.3. Muscle-Invasive
9.4. Non-Muscle-Invasive
10. Bladder Cancer Therapeutics Market, by Treatment Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line
11. Bladder Cancer Therapeutics Market, by Administration Route
11.1. Introduction
11.2. Intravenous
11.3. Intravesical
11.4. Oral
12. Bladder Cancer Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Bladder Cancer Therapeutics Market, by End User
13.1. Introduction
13.2. Home Healthcare
13.3. Hospitals
13.4. Specialty Clinics
14. Americas Bladder Cancer Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Bladder Cancer Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Bladder Cancer Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. F. Hoffmann-La Roche Ltd.
17.3.3. AstraZeneca PLC
17.3.4. Bristol-Myers Squibb Company
17.3.5. Pfizer Inc.
17.3.6. Johnson & Johnson
17.3.7. Eisai Co., Ltd.
17.3.8. Astellas Pharma Inc.
17.3.9. Seagen Inc.
17.3.10. Sesen Bio, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BLADDER CANCER THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BLADDER CANCER THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BLADDER CANCER THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. BLADDER CANCER THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. BLADDER CANCER THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. BLADDER CANCER THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. BLADDER CANCER THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BLADDER CANCER THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY GEMCITABINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY GEMCITABINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TAXANES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CARBOPLATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CISPLATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMO PLUS IMMUNO, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMO PLUS IMMUNO, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMO PLUS TARGETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMO PLUS TARGETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNO PLUS TARGETED, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNO PLUS TARGETED, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CAR-T, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CAR-T, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TIL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TIL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IFN-ALPHA, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IFN-ALPHA, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IL-2, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IL-2, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BACILLUS CALMETTE-GUÉRIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY BACILLUS CALMETTE-GUÉRIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PEPTIDE-BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PEPTIDE-BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NANOMEDICINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NANOMEDICINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY FGFR INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY METASTATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY METASTATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY MUSCLE-INVASIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY MUSCLE-INVASIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-MUSCLE-INVASIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-MUSCLE-INVASIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY INTRAVESICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY INTRAVESICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES BLADDER CANCER THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 215. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 216. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 217. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 218. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 219. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2018-2024 (USD MILLION)
TABLE 220. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2025-2030 (USD MILLION)
TABLE 221. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2018-2024 (USD MILLION)
TABLE 222. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2025-2030 (USD MILLION)
TABLE 223. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 224. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 225. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 228. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 229. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 230. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 231. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 232. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 233. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 234. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 235. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2018-2024 (USD MILLION)
TABLE 236. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2025-2030 (USD MILLION)
TABLE 237. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 238. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 239. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 240. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 241. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 242. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 243. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 244. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 245. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. CANADA BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 250. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 251. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 252. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 253. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2018-2024 (USD MILLION)
TABLE 254. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2025-2030 (USD MILLION)
TABLE 255. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2018-2024 (USD MILLION)
TABLE 256. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2025-2030 (USD MILLION)
TABLE 257. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 258. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 259. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 260. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 261. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 262. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 263. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 264. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 265. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 266. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 267. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 268. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 269. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2018-2024 (USD MILLION)
TABLE 270. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2025-2030 (USD MILLION)
TABLE 271. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 272. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 273. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 274. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 275. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 276. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 277. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 278. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 279. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. MEXICO BLADDER CANCER THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NON-PLATINUM, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY PLATINUM-BASED, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY CYTOKINES, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY VACCINES, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY NOVEL THERAPY, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT STAGE, 2025-2030 (USD MILLION)
TABLE 309. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL BLADDER CANCER THERAPEUTICS MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD M

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Bladder Cancer Therapeutics market report include:
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Johnson & Johnson
  • Eisai Co., Ltd.
  • Astellas Pharma Inc.
  • Seagen Inc.
  • Sesen Bio, Inc.

Table Information

Report AttributeDetails
No. of Pages199
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.97 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.5 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Bladder Cancer Drugs Market by Cancer Type (Muscle-Invasive Bladder Cancer, Non-Muscle-Invasive Bladder Cancer), Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy), Drug Type, Administration Route, Distribution Channel - Global Forecast 2025-2030 - Product Image

Bladder Cancer Drugs Market by Cancer Type (Muscle-Invasive Bladder Cancer, Non-Muscle-Invasive Bladder Cancer), Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy), Drug Type, Administration Route, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 185 Pages
  • Global
From
Bladder Cancer Treatment Drugs - Global Strategic Business Report - Product Image

Bladder Cancer Treatment Drugs - Global Strategic Business Report

  • Report
  • 459 Pages
  • Global
From
Bladder Cancer Therapeutics and Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Bladder Cancer Therapeutics and Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Mitomycin for Injection Market by Application (Bladder Cancer, Breast Cancer, Colorectal Cancer), End User (Ambulatory Surgical Centers, Cancer Specialty Centers, Hospitals & Clinics), Distribution Channel, Dosage Strength, Packaging Type - Global Forecast 2025-2030 - Product Image

Mitomycin for Injection Market by Application (Bladder Cancer, Breast Cancer, Colorectal Cancer), End User (Ambulatory Surgical Centers, Cancer Specialty Centers, Hospitals & Clinics), Distribution Channel, Dosage Strength, Packaging Type - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Bladder Cancer Therapeutics - Global Strategic Business Report - Product Image

Bladder Cancer Therapeutics - Global Strategic Business Report

  • Report
  • 283 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.